Profile data is unavailable for this security.
About the company
Genus plc is a United Kingdom-based animal protein genetics company. The Company supplies breeding animals with desirable characteristics for farmers, enabling them to produce quality meat and milk. Its segments include Genus PIC, Genus ABS and Genus Research and Development. The Genus PIC segment is engaged in the porcine sales business. The Genus ABS segment is engaged in the bovine sales business. Its bovine genetics business sells dairy and beef bull semen and embryos from its superior cattle, which are sold to farmers to breed their cows through artificial insemination. Its porcine genetics business sells genetically superior breeding pigs and semen to farmers, so they can breed commercial pigs with desirable characteristics for pork production. It also provides technical services and advice to farmers, to maximize the performance of its breeding animals in their farms. The Company has supply chain and distribution networks in over 80 countries.
- Revenue in GBP (TTM)668.80m
- Net income in GBP7.90m
- Incorporated1994
- Employees3.44k
- LocationGenus PLCMatrix House, Basing ViewBASINGSTOKE RG21 4DZUnited KingdomGBR
- Phone+44 125 634 7100
- Fax+44 125 647 7385
- Websitehttps://www.genusplc.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Formycon AG | 50.59m | 53.16m | 683.14m | 239.00 | 11.63 | 1.42 | 12.45 | 13.50 | 4.00 | 4.00 | 3.64 | 32.64 | 0.0654 | 34.46 | 1.55 | 255,462.20 | 6.87 | 5.87 | 7.37 | 6.33 | 12.46 | 28.54 | 105.09 | 39.76 | 2.06 | -- | 0.0185 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
| Kuros Biosciences AG | 47.07m | -7.96m | 754.31m | 80.00 | -- | 13.69 | -- | 16.03 | -0.2295 | -0.2295 | 1.73 | 1.64 | 0.6755 | 1.95 | 7.89 | 656,775.00 | -11.42 | -13.47 | -13.53 | -14.84 | 79.13 | 78.73 | -16.91 | -81.48 | 2.17 | -- | 0.0847 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| BioArctic AB | 12.00m | -16.72m | 980.77m | 104.00 | -- | 17.84 | -- | 81.71 | -2.64 | -2.64 | 1.89 | 10.39 | 0.1431 | -- | -- | 1,899,330.00 | -19.94 | 2.24 | -22.13 | 2.56 | 80.72 | 86.52 | -139.32 | 9.76 | -- | -- | 0.0578 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Genus plc | 668.80m | 7.90m | 1.09bn | 3.44k | 138.59 | 1.98 | 21.98 | 1.62 | 0.1186 | 0.1186 | 10.14 | 8.30 | 0.6569 | -- | 5.84 | 194,475.10 | 0.2357 | 3.30 | 0.2742 | 3.87 | -- | -- | 0.3589 | 4.98 | 1.21 | 93.17 | 0.3487 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
| Gubra A/S | 24.97m | -5.19m | 1.11bn | 235.00 | -- | 21.30 | -- | 44.27 | -2.82 | -2.82 | 13.54 | 28.44 | 0.3627 | -- | 8.07 | 1,021,986.00 | -7.54 | -- | -8.33 | -- | 58.74 | -- | -20.79 | -- | -- | -- | 0.1647 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
| Galapagos NV | 252.65m | -50.43m | 1.31bn | 683.00 | -- | 0.5516 | -- | 5.20 | -0.9096 | 3.14 | 4.61 | 43.44 | 0.0704 | 0.3157 | 6.58 | 470,055.70 | -1.41 | -1.48 | -1.55 | -1.65 | 65.10 | -- | -19.96 | -14.42 | 9.95 | -- | 0.004 | -- | 3.47 | -2.02 | 94.42 | -- | 7.04 | -- |
| Evotec SE | 646.53m | -142.59m | 1.49bn | 5.01k | -- | 1.84 | -- | 2.30 | -0.9668 | -0.9668 | 4.39 | 5.46 | 0.3661 | 19.82 | 5.22 | 153,537.30 | -8.07 | -0.0064 | -9.86 | -0.0076 | 13.70 | 24.51 | -22.05 | -0.0178 | 1.99 | -3.11 | 0.3268 | 0.00 | 3.99 | 15.79 | 52.23 | -- | 50.62 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 31 Aug 2024 | 5.15m | 7.80% |
| Vanguard Advisers, Inc.as of 01 Oct 2024 | 3.65m | 5.53% |
| Wellington Management Co. LLPas of 31 Aug 2024 | 3.56m | 5.39% |
| Devon Equity Management Ltd.as of 31 Aug 2024 | 2.91m | 4.41% |
| BlackRock Fund Advisorsas of 31 Aug 2024 | 2.63m | 3.98% |
| Royal London Asset Management Ltd.as of 01 Oct 2024 | 2.44m | 3.69% |
| abrdn Investments Ltd.as of 31 Aug 2024 | 2.40m | 3.64% |
| The Vanguard Group, Inc.as of 31 Aug 2024 | 2.40m | 3.63% |
| Threadneedle Asset Management Ltd.as of 29 May 2024 | 1.94m | 2.94% |
| Capital Research & Management Co. (World Investors)as of 31 Aug 2024 | 1.64m | 2.49% |
